Slagle Financial LLC increased its holdings in shares of Pfizer Inc. (NYSE:PFE – Free Report) by 7.4% in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 64,223 shares of the biopharmaceutical company’s stock after purchasing an additional 4,443 shares during the period. Slagle Financial LLC’s holdings in Pfizer were worth $1,797,000 as of its most recent SEC filing.
Several other hedge funds and other institutional investors also recently bought and sold shares of PFE. Norges Bank purchased a new stake in Pfizer during the 4th quarter valued at approximately $2,129,927,000. Wellington Management Group LLP raised its stake in shares of Pfizer by 4.9% during the fourth quarter. Wellington Management Group LLP now owns 239,209,768 shares of the biopharmaceutical company’s stock worth $6,886,849,000 after purchasing an additional 11,099,024 shares during the last quarter. Charles Schwab Investment Management Inc. lifted its holdings in shares of Pfizer by 8.8% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 104,246,432 shares of the biopharmaceutical company’s stock worth $2,985,783,000 after purchasing an additional 8,473,686 shares during the period. Massachusetts Financial Services Co. MA grew its position in Pfizer by 13.8% in the 4th quarter. Massachusetts Financial Services Co. MA now owns 68,506,441 shares of the biopharmaceutical company’s stock valued at $1,972,300,000 after buying an additional 8,298,920 shares during the last quarter. Finally, Swedbank AB purchased a new stake in shares of Pfizer in the first quarter valued at about $172,902,000. 68.36% of the stock is owned by hedge funds and other institutional investors.
Pfizer Trading Up 0.4 %
PFE stock traded up $0.12 on Friday, hitting $28.90. 21,855,904 shares of the company were exchanged, compared to its average volume of 39,008,852. The company has a debt-to-equity ratio of 0.65, a current ratio of 0.86 and a quick ratio of 0.60. The stock has a market capitalization of $163.76 billion, a price-to-earnings ratio of -481.67, a price-to-earnings-growth ratio of 0.98 and a beta of 0.69. Pfizer Inc. has a twelve month low of $25.20 and a twelve month high of $36.94. The business’s fifty day moving average is $28.83 and its two-hundred day moving average is $27.94.
Pfizer Dividend Announcement
The company also recently announced a quarterly dividend, which will be paid on Tuesday, September 3rd. Stockholders of record on Friday, July 26th will be issued a dividend of $0.42 per share. This represents a $1.68 dividend on an annualized basis and a dividend yield of 5.81%. The ex-dividend date of this dividend is Friday, July 26th. Pfizer’s payout ratio is currently -2,800.00%.
Wall Street Analyst Weigh In
A number of analysts recently commented on PFE shares. Cantor Fitzgerald restated an “overweight” rating and set a $45.00 target price on shares of Pfizer in a research report on Monday. Daiwa America raised Pfizer from a “moderate buy” rating to a “strong-buy” rating in a research note on Wednesday, August 7th. Barclays lifted their price objective on Pfizer from $30.00 to $32.00 and gave the stock an “equal weight” rating in a report on Wednesday, July 31st. Wells Fargo & Company raised their price target on Pfizer from $28.00 to $30.00 and gave the company an “equal weight” rating in a research report on Wednesday, July 31st. Finally, UBS Group lifted their price target on Pfizer from $30.00 to $31.00 and gave the stock a “neutral” rating in a research note on Wednesday, July 31st. Eight research analysts have rated the stock with a hold rating, seven have given a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $34.54.
Check Out Our Latest Report on Pfizer
Pfizer Company Profile
Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.
Featured Stories
- Five stocks we like better than Pfizer
- Do Real Estate Investment Trusts Deserve a Place in Your Portfolio?
- Lumen: Among Top Performers Last Month, Still Has Warning Signs
- High Flyers: 3 Natural Gas Stocks for March 2022
- Baidu’s Strong Quarter Proves a Smart Pick for Michael Burry
- What is the Nikkei 225 index?
- Intuit Beats Q4 Earnings: AI, Dividends, and a Growth Strategy
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.